Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2rrCLL 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Advanced Malignant Solid Neoplasm 1

Interventions

fludarabine phosphate 41Cyclophosphamide 31Mycophenolic Acid 25Whole-Body Irradiation 23Peripheral Blood Stem Cell Transplantation 21Cyclosporine 17Rituximab 16Tacrolimus 15fludarabine 14Antilymphocyte Serum 14Busulfan 12Filgrastim 10Cyclosporins 10Methotrexate 8Sirolimus 7Therapeutics 6Melphalan 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Psychiatric Rehabilitation 4Pharmacogenomic Testing 4Lenalidomide 4Carboplatin 4Allopurinol 4alvocidib 3Thiotepa 3Flow Cytometry 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × dinaciclib × Clear all
NCT01515176 2018-03-15

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡